Safety of intravenous administration of hydrogen-enriched fluid in patients with acute cerebral ischemia: initial clinical studies.
Nagatani K, Nawashiro H, Takeuchi S, Tomura S, Otani N, Osada H, Wada K, Katoh H, Tsuzuki N, Mori K · Medical gas research · 2013
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
The publication “Safety of intravenous administration of hydrogen-enriched fluid in patients with acute cerebral ischemia: initial clinical studies.” is organized in H2HUBB under the research focus injected hydrogen hydrogen safety study 2013. The publication is cited as Nagatani K, Nawashiro H, Takeuchi S, Tomura S, Otani N, Osada H, Wada K, Katoh H, Tsuzuki N, Mori K, Medical gas research, 2013. This uncontrolled human study examined Safety of intravenous administration of hydrogen-enriched fluid in patients with acute cerebral ischemia: initial clinical studies. The abstract describes Human participants; hydrogen delivered as injected or infused hydrogen. The abstract reports: Data from the current study indicate that an H2-enriched intravenous solution is safe for patients with acute cerebral infarction, including patients treated with t-PA. This is an automated editorial draft based on the abstract and requires source review before publication.
Injected hydrogen hydrogen safety study 2013 overview
Most of the results regarding hydrogen (H2) therapy for acute cerebral ischemia are derived from in vitro studies and animal experiments, with only a… Because this is human clinical evidence, relevance depends on participant selection, controls, sample size, treatment duration, adherence, outcome measures, and replication.
Study design and hydrogen intervention
Publication type: Uncontrolled human study. Evidence type: Human clinical evidence. Research model or population: Human participants. Randomized: Yes. Blinding: Open-label. Control status: Unknown.
Delivery method: Injected or infused hydrogen.
Reported findings and scientific interpretation
For this injected hydrogen hydrogen safety study 2013, the study record reports the following: The abstract reports: Data from the current study indicate that an H2-enriched intravenous solution is safe for patients with acute cerebral infarction, including patients treated with t-PA.
These findings should be interpreted as one piece of evidence rather than as a stand-alone medical conclusion. Results can be influenced by the research model, study design, treatment protocol, sample size, outcome selection, statistical methods, and whether the findings have been independently reproduced.
How this research record was prepared
H2HUBB organizes bibliographic details, study design information, intervention data, outcomes, limitations, and safety notes from the available scientific source. Automated classification supports database organization, but it does not replace critical reading of the complete paper. Source identifiers, evidence labels, and delivery-method fields are retained so readers can verify the record and compare it with related publications. A missing field means the information was unavailable or not reported in the structured source; it should not be treated as a negative finding.
Limitations, safety, and original source
Limitations: The abstract alone may not report all methodological limitations; full-text review is required.
Safety: The abstract did not provide detailed safety or adverse-event information.
This H2HUBB page is an educational research record, not medical advice. Review the original scientific source for the complete methods and results. Continue exploring the H2HUBB Molecular Hydrogen Research Library to compare evidence types, delivery methods, and related topics.